FIELD study: Difference between revisions
Rim Halaby (talk | contribs) |
Rim Halaby (talk | contribs) |
||
| Line 42: | Line 42: | ||
==Publications== | ==Publications== | ||
The administration of fenofibrates among patients with diabetes and either low [[HDL]] or hypertension significantly decreased the rate of cardiovascular events. The reduction of cardiovascular events with the administration of fenofibrates was most pronounced among patients with [[hypertriglyceridemia]].<ref name="pmid18984774">{{cite journal| author=Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D et al.| title=Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. | journal=Diabetes Care | year= 2009 | volume= 32 | issue= 3 | pages= 493-8 | pmid=18984774 | doi=10.2337/dc08-1543 | pmc=PMC2646035 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18984774 }} </ref> | The administration of fenofibrates among patients with diabetes and either low [[HDL]] or hypertension significantly decreased the rate of cardiovascular events. The reduction of cardiovascular events with the administration of fenofibrates was most pronounced among patients with [[hypertriglyceridemia]].<ref name="pmid18984774">{{cite journal| author=Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D et al.| title=Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. | journal=Diabetes Care | year= 2009 | volume= 32 | issue= 3 | pages= 493-8 | pmid=18984774 | doi=10.2337/dc08-1543 | pmc=PMC2646035 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18984774 }} </ref> | ||
Latest revision as of 03:05, 19 August 2014
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
FIELD study On the Web |
|
American Roentgen Ray Society Images of FIELD study |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Official Title
Fenofibrate Intervention and Event Lowering in Diabetes
Objective
The objective of this study is to determine the risk of fatal coronary heart disease among subjects with type 2 diabetes who are administered fenofibrate.
Timeline
| Timeline | |
| Start Date | 01/01/1998 |
| End Date | 31/12/2005 |
| Status | Completed |
Study Description
| Study Description | |
| Study Type | Randomized |
| Study Details | |
| Condition | Diabetes Mellitus type 2 |
| Intervention | Fenofibrate Placebo |
| Population Size | 9,795 |
Publications
The administration of fenofibrates among patients with diabetes and either low HDL or hypertension significantly decreased the rate of cardiovascular events. The reduction of cardiovascular events with the administration of fenofibrates was most pronounced among patients with hypertriglyceridemia.[1]
References
- ↑ Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D; et al. (2009). "Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study". Diabetes Care. 32 (3): 493–8. doi:10.2337/dc08-1543. PMC 2646035. PMID 18984774.